Pyridostigmine: using a cholinesterase inhibitor to activate the cholinergic anti-inflammatory pathway in patients with CRPS-1

Phase 2

Completed

• Conditions: pijn syndroom; dystrophy; post-traumatic dystrophy; reflex sympathetic dystrophy

• Registration Number: NL-OMON33787
• Lead Sponsor: Vrije Universiteit Medisch Centrum

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 6 May 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 10

Inclusion Criteria

CRPS-1 according to Veldman criteria
Unsatisfactory results of convential therapy
Minimum age 18

Exclusion Criteria

Medical condition of the contralateral extrimity
astma
cardiac problems
hyperthyroidism
epilepsy
parkinson
kreatinin > 100
severe psychiatric disorder
active malignant disease
other chronic pain syndrome

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Inflammatory signs measured according to the TREND protocol (app 1)<br /><br>(temperature, motor function, swelling)<br /><br>Pain score obtained by VAS score pain diaries. </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Side effects of Pyridostigmine bromide measured by the pyridostigmine bromide<br /><br>side effect scale (app 2)<br /><br>Cholinesterase in plasma<br /><br>Oxidative stress in blood</p><br>